VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results - Markets Insider

VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial ResultsMarkets Insider"Building on our significant progress last quarter, our team is prepared and eager to launch, during the current quarter, our AV-101 Phase 2 clinical development program, initially focused on adjunctive treatment of Major Depressive Disorder patients ...and more »